GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GlaxoSmithKline Pharmaceuticals has informed the exchanges that its trading window will be closed starting Wednesday, 1st April 2026, in line with SEBI's insider trading rules. The window will remain shut until 48 hours after the company announces its audited financial results for the fourth quarter and full year ended 31st March 2026. During this period, designated insiders cannot buy or sell shares of the company. The exact date of the board meeting to approve these results has not yet been announced and will be communicated later.
This is a routine compliance disclosure and does not directly affect shareholders. It signals that the company's Q4 and full-year FY26 earnings are approaching, which investors should watch for as the next material catalyst for the stock.